Item 9 Labs Corp.
INLBOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$70181
P/E Ratio—
52W High$0.0001
52W Low$0.0001
Item 9 Labs Corp. (INLB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
INLB · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2023Report Date: Aug 21, 2023EPS Actual
-$0.06
Est. -$0.03 · -100.0%
Revenue
$0.01B
Est. $0.00B · +11.6%
Fiscal Period
Q3 FY2023
FY ends December
Report Date
Aug 21, 2023
After Market Close
▼ Miss EPS▲ Beat Revenue
INLB reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$3.83
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$3.83
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 18, 2026 | -$0.04 | — | — | — | $0.01B | — |
| ◌ Q2 FY2026 | May 29, 2026 | — | — | — | — | — | — |
| ◌ Q2 FY2026 | May 19, 2026 | -$0.04 | — | — | — | $0.01B | — |
| ◌ Q1 FY2026 | Feb 27, 2026 | -$0.04 | — | — | — | $0.01B | — |
| ◌ Q4 FY2024 | Nov 18, 2024 | — | — | — | — | — | — |
| ◌ Q3 FY2024 | Aug 9, 2024 | — | — | — | — | $0.00B | — |
| ◌ Q2 FY2024 | May 31, 2024 | — | — | — | — | $0.00B | — |
| ◌ Q4 FY2023 | Nov 29, 2023 | -$0.03 | — | — | — | $0.01B | — |
Q3 FY2026
Aug 18, 2026
EPS Actual
—
EPS Est.
-$0.04
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 29, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 19, 2026
EPS Actual
—
EPS Est.
-$0.04
EPS Surpr.
—
Revenue
—
Q1 FY2026
Feb 27, 2026
EPS Actual
—
EPS Est.
-$0.04
EPS Surpr.
—
Revenue
—
Q4 FY2024
Nov 18, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2024
Aug 9, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
May 31, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2023
Nov 29, 2023
EPS Actual
—
EPS Est.
-$0.03
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2028 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Q2 FY2028 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Q1 FY2028 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q4 FY2027 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Q3 FY2027 | $-0.19 | $-0.19 | $-0.19 | 1 |
| Q2 FY2027 | $-0.03 | $-0.03 | $-0.03 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q3 FY2023 | Aug 21, 2023 | -100.0% | $0.02 | $0.02 | +13.33% |
| ▲ Q2 FY2023 | May 22, 2023 | +40.0% | $0.04 | $0.04 | -4.19% |
| ▲ Q1 FY2023 | Feb 14, 2023 | +40.0% | $0.17 | $0.20 | +21.21% |
| ▼ Q1 FY2023 | Jan 13, 2023 | -400.0% | $0.23 | $0.19 | -16.30% |
Q3 FY2023+13.33%
Report Date
Aug 21, 2023
EPS Beat/Miss
-100.0%
Price Before
$0.02
Price After
$0.02
Q2 FY2023-4.19%
Report Date
May 22, 2023
EPS Beat/Miss
+40.0%
Price Before
$0.04
Price After
$0.04
Q1 FY2023+21.21%
Report Date
Feb 14, 2023
EPS Beat/Miss
+40.0%
Price Before
$0.17
Price After
$0.20
Q1 FY2023-16.30%
Report Date
Jan 13, 2023
EPS Beat/Miss
-400.0%
Price Before
$0.23
Price After
$0.19
Avg Beat Reaction+8.51%
Avg Miss Reaction-1.49%
Beat Rate2 / 4 quarters
Largest Move+21.21% (Q1 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: INLB ends December
Item 9 Labs Corp. (INLB) most recently reported earnings on August 21, 2023 for Q3 FY2023, posting EPS of $-0.06 — missing the analyst consensus of $-0.03 by -100.0%. The next INLB earnings date is expected around September 1, 2026.
Each quarter, investors track INLB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. INLB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
INLB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
INLB earnings · 5 questionsItem 9 Labs Corp.'s next earnings report is expected around September 1, 2026. INLB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; INLB historically reports after market close (AMC).
INLB earnings datewhen is INLB earningsINLB next earnings datewhen does INLB report earningsINLB earnings calendar
▸ Source: FMP · Item 9 Labs Corp. SEC filings · US GAAP · Item 9 Labs Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026